Bio-Rad Laboratories, a life science research products specialist, has expanded its Pioneer Antibody Discovery Platform service with the addition of bispecific antibody generation and screening services.
The advancement is based on the company's SpyLock Technology, which will enable customers to rapidly generate and screen bispecific antibodies to identify effective combinations for development.
The Pioneer Platform comprises a human synthetic phage display library of 225bn unique Fab antibodies, while the SpyDisplay technology allows the delivery of antibody candidates in a timely manner.
Bio-Rad claims that the technology can also be customised to meet the needs of any project.
Technology for a range of applications
The Pioneer Platform is being used across organisations globally, with applications including immuno-oncology and infectious diseases.
The company has entered into a partnership with Salipro Biotech, which aims to identify quality antibody leads against GPCR targets. The collaboration has already generated multiple leads against one of the targets, with affinities apparently exceeding the existing first-in-class antibody.
The new antibodies exhibited promising functional activity and offer the potential for enhanced efficacy and novel immuno-oncology therapeutic avenues.
“Progress in the development of various platforms for generating bispecific antibodies has led to an increase in these clinically superior therapeutics passing through clinical trials and achieving market approvals. The addition of SpyLock as part of our Pioneer Platform provides a solution to support the screening of bispecific antibodies,” said Marketing Manager of Custom Antibodies at Bio-Rad, John Cardone.
“The continued expansion of our antibody services reflects our commitment to creating novel support options for our customers, enabling researchers to screen therapeutic bispecific antibody candidates in industry-leading timelines.”
